Sierra Oncology, Inc. (SRRA)
| Market Cap | 210.01M |
| Revenue (ttm) | 300,000 |
| Net Income (ttm) | -80.90M |
| Shares Out | 11.63M |
| EPS (ttm) | -7.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $17.93 |
| Previous Close | $18.40 |
| Change ($) | -0.47 |
| Change (%) | -2.55% |
| Day's Open | 18.33 |
| Day's Range | 17.70 - 18.44 |
| Day's Volume | 17,592 |
| 52-Week Range | 10.02 - 20.43 |
For all practical purposes, Sierra Oncology today is a single product company, solely focused on its most advanced product, momelotinib, which is targeted at Myelofibrosis. There will likely be easier t...
- Ms. Thomson brings extensive strategic, transactional and intellectual property experience as Sierra prepares for potential transition into a commercial company -
Sierra Oncology, Inc (SRRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sierra Oncology, Inc. (SRRA) Nick Glover on Q4 2019 Results - Earnings Call Transcript
Sierra Oncology (SRRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.
Sierra Oncology has been struggling lately, but the selling pressure may be coming to an end soon.
About SRRA
Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly know... [Read more...]
| Industry Biotechnology | IPO Date Jul 16, 2015 |
| CEO Stephen Dilly | Employees 69 |
| Stock Exchange NASDAQ | Ticker Symbol SRRA |
Analyst Forecasts
According to 4 analysts, the average rating for SRRA stock is "Strong Buy." The 12-month stock price forecast is 27.75, which is an increase of 54.77% from the latest price.